Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: Effectively treated with Pirfenidone
<p>The coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has led to a pandemic situation. According to the WHO classification, COVID-19 patients could be classified with severity as uncomplicated illness, mild pneumonia, severe pneumonia,...
I tiakina i:
Ngā kaituhi matua: | Zhan Xi (Author), Zhao Zhigang (Author), Li Ting (Author) |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
Archives of Pulmonology and Respiratory Care - Peertechz Publications,
2020-06-23.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ngā tūemi rite
-
Role of pirfenidone in the management of pulmonary fibrosis
mā: Meyer KC, me ētahi atu.
I whakaputaina: (2017) -
Pirfenidone treatment of idiopathic pulmonary fibrosis
mā: Ye Gan, me ētahi atu.
I whakaputaina: (2011) -
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
mā: Maria Chianese, me ētahi atu.
I whakaputaina: (2024) -
Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
mā: Wencheng Yu, me ētahi atu.
I whakaputaina: (2017) -
Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
mā: José M. Serra López-Matencio, me ētahi atu.
I whakaputaina: (2021)